Heralding a new era in kidney disease research and treatment: The CREDENCE trial
The landmark clinical trial, CREDENCE, transformed the status quo in diabetic kidney disease research by identifying the first new treatment in almost 20 years. Building on The George Institute’s long history of research in diabetes, researchers showed a class of diabetes medication - SGLT2 inhibitors - reduces the risk of cardiovascular disease and prevents kidney failure in people with type 2 diabetes. Their work has ushered in a new era of research that led to changes in treatment guidelines and transformed practice worldwide. As a result, many millions of lives and billions of dollars in healthcare costs will be saved by averting heart disease, kidney failure and other health complications of diabetes.